Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T15:03:20.511Z.
Calculation as of: 2026-10-06T15:03:20.511Z.
Quote observation: 2026-10-06T14:56:43.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 93c5e63ae445a2e41424364838d154d4df2cbb6a4085a726ee5a5ae15b1ce67b
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$65.07M
Price/OCF Ratio
N/A
TTM Avg
1.86
3Y Avg
1.86
5Y Avg
1.86
Market Cap
$61.23M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kalaris Therapeutics Inc (KLRS) | $63.30M | N/A | N/A | N/A | N/A |
| Alps Group Inc (ALPS)vs › | $63.23M | N/A | N/A | N/A | N/A |
| InterCure Ltd. (INCR)vs › | $64.68M | 6.86 | 5.29 | 5.29 | 30.61 |
| Heron Therapeutics, Inc. (HRTX)vs › | $65.07M | N/A | 1.86 | 1.86 | 1.86 |
| PDS Biotechnology Corporation (PDSB)vs › | $61.23M | N/A | N/A | N/A | N/A |
| Cingulate Inc. (CING)vs › | $65.73M | N/A | N/A | N/A | N/A |
| Gossamer Bio, Inc. (GOSS)vs › | $65.93M | N/A | 35.67 | 35.67 | 35.67 |
| Adicet Bio, Inc. (ACET)vs › | $60.30M | N/A | 93.25 | 93.25 | 93.25 |
| MiNK Therapeutics, Inc. (INKT)vs › | $59.51M | N/A | N/A | N/A | N/A |
| Fractyl Health, Inc. (GUTS)vs › | $59.23M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
